Functional genomic identification of predictors of sensitivity and mechanisms of resistance to multivalent 2nd generation TRAIL-R2 agonists.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-21-0532
Abstract: Multivalent second-generation TRAIL-R2 agonists are currently in late pre-clinical development and early clinical trials. Herein, we use a representative 2nd generation agent, MEDI3039, to address two major clinical challenges facing these agents: lack of predictive… read more here.
Keywords: generation; caspase; trail agonists; resistance ... See more keywords